Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...
BioInvent International has secured a US patent for its antibody and concomitant target discovery technology F.I.R.S.T., a novel and unique discovery method, which allows for antibodies and disease targets to be identified simultaneously. ...
Laboratory Corporation of America Holdings (LabCorp) has announced that its fourth generation human immunodeficiency virus (HIV) antigen/antibody combination assay for screening of HIV infection is now available. In addition to the HIV ...
Tags: hiv, hiv antigen, hiv cure, hiv assays
Integral Molecular, a biotechnology company, has announced the issuance of a new patent and patent family by the United States Patent and Trademark Office (USPTO) covering the composition of matter for its Lipoparticle technology. This ...
Tags: Lipoparticle Technology, USPTO
One Lambda, a part of Thermo Fisher Scientific, has obtained CE Mark approval for its C1qScreen assay in Europe. Utilizing Luminex-based single antigen beads, the C1qScreen solid-phase assay allows clinicians to further characterize ...
Tags: One Lambda, C1qscreen Assay
Scientists from IBM and Singapore’s Institute of Bioengineering and Nanotechnology (IBN) published a breakthrough drug-delivery technique, demonstrating the first biodegradable, biocompatible and non-toxic hydrogel that can deliver ...
Tags: Cancer Drug, Medicine
The US Food and Drug Administration (FDA) has approved Roche's new drug Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy for treatment of patients with chronic lymphocytic leukemia (CLL) who have not previously been ...
Tags: Combination Vaccine, Medicine
Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of Rixubis, recombinant factor IX for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. ...
Tags: Baxter, European Medicines Agency
Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...
Eli Lilly and Company has received priority review status from the US Food and Drug Administration (FDA) for its ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial ...
Tags: Cancer Drug, FDA Priority
US-based biopharmaceutical company Immunomedics has announced the issuance of a US patent to its majority-owned subsidiary, IBC Pharmaceuticals, for ‘Novel Strategies for Improved Cancer Vaccines’. The new patent concerns ...
GlaxoSmithKline (GSK) and Danish biotechnology firm Genmab have filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of its leukaemia drug Arzerra (ofatumumab) in combination ...
Tags: GlaxoSmithKline, CLL Patients
AstraZeneca's global biologics research and development division MedImmune will acquire Spirogen, a biotech firm focused on antibody-drug conjugate technology for use in oncology. Spirogen's complete shares will be purchased by MedImmune ...
Tags: biologics research, AstraZeneca
BioInvent International and Bayer Pharma have extended their collaboration to develop antibodies from BioInvent's n-CoDeR libraries. As part of the deal, which is an extension of the 2008 license agreement, Bayer will broaden its access ...
US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...
Tags: Immunogen, Novartis, ADC Technology